Menopausal Hormone Therapy

Definition

Menopausal hormone therapy is the clinician-guided use of estrogen, with endometrial protection when needed and selected use of other hormones, to treat menopause symptoms after considering timing, route, formulation, uterine status, risks, contraindications, and patient priorities.

Current Synthesis

The Haver episode rejects a single yes-or-no judgment about hormone therapy. It presents systemic estrogen as the most effective treatment for vasomotor symptoms, but argues that the clinical meaning changes with age, time since menopause, existing cardiovascular disease, route, dose, and the need for progesterone in a person with a uterus. Haver favors transdermal or other non-oral estradiol routes when appropriate because oral delivery passes through the liver and can affect clotting-related physiology.

Timing is central but not absolute. Starting nearer the menopause transition is presented as a different risk context from first considering systemic therapy after age 60 or more than ten years after menopause. Later consideration is not framed as automatically impossible; it calls for more deliberate cardiovascular, stroke, bleeding, cancer, liver, and clot-risk review. Local vaginal estrogen is separated into Genitourinary Syndrome of Menopause Care because its indication and exposure pattern differ from systemic therapy.

Key Claims

• Systemic hormone therapy is presented as the most effective treatment for hot flashes and related vasomotor symptoms.
• Age and time since menopause materially change the risk-benefit conversation.
• Route matters; the source prefers non-oral estradiol when systemic estrogen is appropriate.
• People with a uterus generally need endometrial protection when using systemic estrogen.
• Hormone-sensitive cancer, unexplained uterine bleeding, active clot treatment, and severe liver disease are named as reasons to avoid or delay systemic therapy.
• Testosterone use in women is narrower and monitoring-dependent because the source notes the absence of an FDA-approved female product.

Evidence

• Symptom treatment - How to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver calls hormone therapy the gold-standard treatment for vasomotor symptoms.
• Timing interpretation - How to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver distinguishes initiation around ages 50 to 59 from first consideration after age 60 or more than ten years after menopause.
• Route and formulation - How to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver discusses patches, gels, sprays, rings, oral progesterone, symptom titration, and liver first-pass effects.
• Contraindication boundary - How to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver names hormone-sensitive cancers, unevaluated abnormal bleeding, active clot treatment, and severe liver disease as major safety constraints.

Counterevidence & Qualifications

The page records one clinician’s interpretation of the Women’s Health Initiative and subsequent evidence, not an independent guideline or patient-specific recommendation. Breast-cancer, cardiovascular, stroke, clot, and mortality effects depend on population, formulation, route, timing, uterine status, baseline disease, and study design. Symptom relief does not remove the need for ongoing review, and testosterone, compounded products, and late initiation carry additional uncertainty.

What Changed

• Created a dedicated synthesis separating timing, route, formulation, indication, and contraindication from blanket pro- or anti-hormone positions.

Related Concepts

• Menopause Clinical Shared Decision-Making / 更年期临床共同决策 - parent care process for matching treatment to symptoms, risks, and priorities.
• Genitourinary Syndrome of Menopause Care - local-estrogen branch distinct from systemic symptom treatment.
• Perimenopause Brain Metabolism - symptom and brain-energy context that can prompt clinical discussion.
• Medical Risk Management - contraindication, monitoring, and risk-benefit boundary.
• Context-Dependent Biomedical Interventions - general rule that intervention value changes with patient and timing context.